CelLBxHealth (AGL) Emerging Growth Conference 79 summary

Company overview and technology

• Introduced a patented Parsortix system for isolating circulating tumor cells (CTCs) from blood, enabling a new approach to cancer diagnosis and treatment.

• The system automates blood processing, separating rare cancer cells from billions of blood cells for subsequent analysis.

• Achieved FDA clearance, making it the only product approved for harvesting cancer cells from blood for analysis.

• Enables analysis of DNA, RNA, protein expression, and cell morphology, providing a comprehensive cancer profile.

• Over 100 peer-reviewed publications from 42 independent cancer centers across 24 cancer types validate the system's broad applicability.

Market opportunity and clinical impact

• The technology addresses the need for repeat, minimally invasive biopsies as cancer evolves, overcoming limitations of traditional tissue biopsies.

• Applicable for early diagnosis, treatment selection, minimal residual disease assessment, and remission monitoring.

• Remission monitoring with CTCs can detect cancer recurrence earlier than current imaging methods.

• High drug costs and low response rates highlight the need for better patient selection, which the system supports.

• Independent studies show CTC presence is a lead indicator for cancer progression, enabling earlier intervention.

Commercialization and pharma partnerships

• Commercialization is focused on partnerships with large pharmaceutical companies for assay development and clinical trials.

• Pharma benefits include up-to-date patient selection, real-time monitoring, and development of companion diagnostics.

• Current contracts include projects with AstraZeneca and Eisai, targeting protein analysis on CTCs for drug development.

• Each drug project can generate significant revenue, with Phase II studies yielding GBP 1–3 million and Phase III up to GBP 45 million.

• Long-term annuity revenue is expected from companion diagnostic use as drugs reach the market.